The prescription rate of DAT decreased from 14.3 to 10.5% even despite PIONEER AF-PCI study provided superior safety with DAT, a P2Y12 inhibitor plus rivaroxaban (15 mg once daily) over TAT with warfarin. This evidence concerns the gene P2RY12 and atrial fibrillation.